



## NEWS RELEASE

### **For Further Information Contact:**

Roy Wolvin  
Nymox Pharmaceutical Corporation  
1-800-93NYMOX  
[www.nymox.com](http://www.nymox.com)

### **For Immediate Release:**

## **Nymox Reports Update on NX-1207 Study Results, Marketing Plans and Activities**

HASBROUCK HEIGHTS, NJ (December 12, 2007) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reported today an update on recent study results and development activities for the Company's NX-1207 drug for benign prostatic hyperplasia (BPH). The results of the recently completed 2 year double blind follow-up study demonstrated the durable effect of the drug, which is of fundamental interest and importance to urologists and their patients. The study was conducted at 24 U.S. sites and involved 103 unselected patients.

"The study showed that many patients required no further treatment for 2 years after a single office visit administration that took 5-10 minutes. That level of efficacy is superior to known drugs, and NX-1207 has none of the impotence, loss of libido, retrograde ejaculation, dizziness, fainting, weakness, breast enlargement, and the rest of the long list of side effects of other BPH drugs", said Brian Doyle, Global Sales Manager for Nymox.

Nymox has encountered serious interest and several term sheet offers from potential large pharmaceutical company marketing partners for NX-1207. The Company is presently involved with furthering the process, as well as due diligence procedures. The Company is carefully considering its options for future marketing arrangements for NX-1207.

The results from the 2 year follow-up study of NX-1207 were reported in the current issue of *Urology Times* (Dec. 6, 2007) in a report entitled "BPH treatment offers promising 2-year results". *Urology Times* is a leading news source for urologists, with an editorial board of nationally recognized experts in urology. This was a placebo controlled double blind U.S. trial. The data showed that a single treatment with NX-1207 produced durable significant improvement. Statistical analysis of the controlled data showed that the results for NX-1207 reached statistical significance ( $p < .05$ ) when the comparison was done to a baseline matched group of placebo controls.

Nymox has recently conducted a formal survey of a group of expert urologists in the U.S. which has helped the Company to refine its marketing strategy for NX-1207. Urologists have expressed a strong interest in NX-1207, and a preference for its route of administration.

There has been wide interest shown by urologists in this new drug, based on public comments made by doctors at presentations of NX-1207 data at meetings of the American Urological Association in Boston, Colorado Springs, Bermuda, and Scottsdale this year. The Company has received a large number of emails and calls from patients and doctors throughout the U.S. and internationally, interested in participating in clinical trials and wanting to learn more about the drug.

“BPH is an under-treated condition. We believe that an effective treatment, particularly one that is simple to administer in the office and essentially painless – and which has negligible side effects, in particular no sexual side effects – will have a great chance to grow the BPH treatment population. It is estimated that over 100 million men in the G7 countries have BPH, and yet less than 25% of them receive any treatment at all. That should dramatically increase if the treatment was more effective and ‘user friendly’. Men prefer not to have surgery, and they would prefer not to take pills every day of their lives, with frequent sexual side effects, like impotence and loss of libido”, said Mr. Doyle.

More information about Nymox is available at [www.nymox.com](http://www.nymox.com), email: [info@nymox.com](mailto:info@nymox.com), or 800-936-9669.

*This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox’s filings with the United States Securities and Exchange Commission and other regulatory authorities.*